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ABSTRACT 47	
 48	
The WHO 2035 vision is to reduce tuberculosis (TB) associated mortality by 95%. 49	
While low burden, well-equipped developed economies can expect to see this goal 50	
achieved, it is challenging in low – and middle-income countries bearing the highest 51	
burden of TB.  Inadequate diagnosis leads to inappropriate treatment and poor clinical 52	
outcomes. The rollout of Xpert MTB/RIF has demonstrated that molecular 53	
diagnostics can produce rapid diagnosis and treatment initiation.  Strong molecular 54	
services are still limited to regional or national centres. Part of the implementation 55	
delay is due to resources but part due to the suggestion that such techniques are too 56	
challenging for widespread implementation.  We have successfully implemented a 57	
molecular tool for rapid monitoring of patient treatment response to anti-tuberculosis 58	
therapy in three high TB burden countries in Africa. Thus, we discuss the challenges 59	
facing TB diagnosis and treatment monitoring; and draw from our experience 60	
establishing molecular treatment monitoring platforms to provide practical insights 61	
into successful optimization of molecular diagnostic capacity in resource constrained 62	
TB high burden settings. We recommend a holistic health-system wide approach for 63	
molecular diagnostic capacity development addressing human resource training, 64	
institutional capacity development, streamlined procurement systems, and 65	
engagement with the public, policy-makers and implementers of TB control 66	
programmes. 67	
 68	
 69	
 70	
 71	
 72	
 73	
 74	
 75	
 76	
 77	
 78	
 79	
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INTRODUCTION 80	
 81	
Tuberculosis (TB) is a global emergency that claims over a million lives per year(1). 82	
The WHO vision is to attempt global TB elimination achieving 90% incidence – and 83	
95% mortality reduction by 2035(1,2). This is an ambitious target as the highest 84	
burden of TB is in the poorly resourced parts of the world. To achieve success, better 85	
diagnostic and treatment systems must be put in place(3). Indeed the reduction of 86	
mortality achieved so far is attributed to improvement in treatment driven by better 87	
diagnosis and treatment monitoring(4). The 3 million new TB cases who go 88	
undetected by the system must be found if the disease is to eliminated(1,3). Here, we 89	
draw on our experience implementing a molecular assay for rapid assessment TB 90	
treatment response in three TB high burden countries, Malawi, Mozambique & 91	
Tanzania to discuss the challenges facing TB diagnosis and treatment, and give 92	
insights into what needs to be done to optimize molecular diagnostic capacity and put 93	
the TB high burden countries on the road to TB elimination. The study was conducted 94	
under the consortium Pan-African Biomarker expansion programme (PANBIOME) 95	
evaluating novel biomarkers for TB diagnosis and treatment. Treatment response of 96	
200 patients from 4 sites in the three Southeast African countries was monitored using 97	
molecular bacterial load assay (MBLA) along traditional culture methods and smear 98	
microscopy (SM) over a period of 3 months. 99	
 100	
TB DIAGNOSIS AND ASSOCIATED CHALLENGES 101	
Despite bearing two thirds of the world TB burden, the developing world has the 102	
lowest of diagnostic and treatment capacity. Sub-Saharan Africa, which accounts for 103	
≈50%, diagnoses depends mainly on passive detection by healthcare workers who, 104	
too, are rare (18 physicians to every 100000 people)(5). SM, which is less sensitive 105	
and cannot differentiate between live and dead bacteria remains the main tool for TB 106	
diagnosis in these countries(6,7). The more sensitive culture is only available in 107	
national or regional laboratories and hardly accessible to patients in rural areas.  108	
The rollout of Cepheid’s Xpert MTB/RIF that simultaneously detects Mycobacterium 109	
tuberculosis (Mtb) and resistance to Rifampicin, has revolutionized the diagnosis of 110	
TB by offering a rapid and accurate detection of Mtb and subsequently shortening the 111	
	 4	
time to initiation of treatment(8,9).  However, Xpert MTB/RIF remains a centralized 112	
service, which limits it impact on the majority of patients(10,11). This means that the 113	
utility of good molecular diagnostics to be fully realised, the services must be 114	
decentralised and taken closer to patients. It is important to note that in most sub-115	
Saharan countries the current coverage of Xpert MTB/RIF service thrives on a 116	
subsidy from FIND and associated development partners 117	
(www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/ 118	
xpert_mtb_rif.html) without which the situation would be worse. 119	
Investing in energy efficient point of care molecular diagnostics will increase 120	
applicability in low-income countries(12). Molecular techniques offer a rapid, 121	
sensitive and specific assessment of treatment response of both pulmonary and 122	
extrapulmonary TB(13), but they require power to run. Building partnerships between 123	
developers and researchers in TB high burden settings will enable production of 124	
environment customized diagnostic appliances that meet the need as well as fit the 125	
bill. 126	
 127	
TB TREATMENT MONITORING AND ASSOCIATED CHALLENGES 128	
 129	
Although improvement has been made in pathogen detection TB treatment response 130	
monitoring still lags behind.  Failure to detect poor response to anti-TB therapy, 131	
coupled with rounds of inadequate and/or failing treatment is the main reason for 132	
emergence of new drug resistance(14). The current TB monitoring guideline is smear 133	
SM and culture if smear positive at 3-, 5- or 6 months (15). The SM limit of detection 134	
is estimated at 104 CFU/ml implying that many patients are smear negative when they 135	
still have a significant bacterial load(16). Smear predicts culture result increasingly 136	
poorly as treatment progresses.  Culture, which is the gold standard for both diagnosis 137	
and treatment monitoring of TB, has many challenges that compromise its use in the 138	
management of TB (15).  139	
 140	
The decontamination process to remove non-mycobacterial organisms reduces 141	
viability M. tuberculosis, which reduce test sensitivity.  It is challenging to perform 142	
and contamination rates of 17 - 30% in some settings have been reported(17,18). With 143	
contaminants the time to culture positivity does not accurately reflect the number of 144	
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Mtb and is, thus, useless to assess treatment response. M. tuberculosis grows very 145	
slowly with average generation time of ~24h (19,20) translating to average 21 days on 146	
solid - or 12 days in liquid culture for growth to be detected in sputum samples from 147	
patients with pulmonary tuberculosis (21). Moreover, samples can only be declared 148	
culture negative after 42 days in the automated liquid culture system, Mycobacterium 149	
Growth Indicator tube (MGIT) or eight weeks in LJ medium (22). Delay in achieving 150	
the results compromises the utility of culture as a marker for treatment response. 151	
Moreover full time incubation requiring constant electricity supply and need for 152	
expensive bio-containment facilities make liquid culture less accessible to resource 153	
poor settings(23). It is most likely that SM and culture turn negative earlier than 154	
actual clearance of active TB disease (24). A recent publication indicates that culture 155	
has a limited role in predicting the efficacy of regimens(25). 156	
 157	
To improve treatment monitoring, we propose replacing culture with user-friendly 158	
molecular based assays to quicken the process and improve accuracy of monitoring 159	
TB treatment response. We have completed a multi-site performance evaluation of a 160	
treatment-monitoring assay (Molecular bacterial load assay)(26,27). The assay 161	
quantifies viable mycobacterial cells in patient sputum by detecting ribosomal RNA 162	
specific to Mtb and reference to an internal extraction and amplification control. The 163	
specificity to Mtb removes the step for removing non-TB contaminants and offers a 164	
result in 4h. The measured bacterial load falls with treatment for patients with 165	
sensitive bacterial load and vice versa for resistant TB (26,27).  166	
 167	
 168	
 169	
SYSTEMIC CHALLENGES 170	
 171	
Beyond technical challenges, systemic failures or shortages further complicate the 172	
process of tuberculosis diagnosis and treatment monitoring: 173	
 174	
Infrastructure: Consistent supply of water and electricity is essential for good 175	
diagnostic and clinical services. The harsh reality is that these utilities remain a 176	
scarcity in most low-income TB high burden countries. The good Xpert MTB/RIF is 177	
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still unavailable in many rural areas because of limited power supply. The need for 178	
stable power supply was highlighted in A TB REACH study that evaluated 179	
programmatic implementation of Xpert MTB/RIF(28). Likewise the automated MGIT 180	
liquid culture system that requires full time incubation cannot operate in areas where 181	
there is no electricity.  182	
 183	
Human resource: The number of skilled laboratory technologists is low and the 184	
turnover is high as they are in demand by NGOs, industry and the private health 185	
sector. Critically biomedical engineering support in sub-Saharan Africa is sub-optimal 186	
causing delays in servicing. Instrument failure interrupts the flow of diagnostic and 187	
treatment service delivery as well as compromising research.  188	
 189	
Procurement bottlenecks: The process of procuring laboratory supplies is complex 190	
and results in delayed service delivery. Creswell and colleagues reported a median 191	
delay of 40 days to procure Xpert MTB/RIF and associated supplies(28). Our 192	
experience shows that some orders can take longer than this, 2 - 3 months to be 193	
delivered. The procurement difficulties are not only due to supplies coming from far 194	
to reach overseas suppliers but also in due to the bureaucratic custom clearance 195	
system that treats not-for-profit laboratory supplies as commercial goods to the extent 196	
that some consignment expire in customs depots. The complex clearance system is 197	
perhaps due to the government’s policy to crack down on tax evasion by private 198	
importers macerating as not-for-profit. Procurement bottlenecks stand in the way of 199	
early diagnosis and treatment and have a knock-on effect on patient clinical outcome. 200	
 201	
Financing and operational bottlenecks: More than 50% of TB control in most sub-202	
Saharan countries is donor funded and so the current global US$2 billion deficit 203	
directly affects the national TB control programmes(1). Poor financing results in 204	
failure to hire needed personnel, uptake of new diagnostics and purchase of vital 205	
medicines. This also stifles complementary system services such as records, 206	
surveillance and community engagement.  207	
 208	
We believe that systemic challenges could be addressed by taking a holistic approach 209	
of capacity development.  Development of government – research community 210	
partnerships would improve infrastructural and human resource shortages, and 211	
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procurement bottlenecks. An EDCTP commissioned study on the state of health 212	
research in Africa found that one of the major challenges was policy makers being 213	
unaware of the value of health research and innovation(29). This suggests that 214	
engaging policy makers and bringing them on board as important stake holders is 215	
crucial for optimising molecular diagnostics capacity in high TB burden settings, 216	
 217	
We also recommend the following lessons that we learned during implementation 218	
of the molecular TB treatment-monitoring programme in Southeast Africa: 219	
 220	
Listening and learning to understand the needs and context: Conducting a site audit 221	
to assess the needs prior to commencement of the study in order to set up priorities 222	
and ensuring that capacity development meets the needs on the ground. For instance 223	
in Mozambique we were able to build on existing molecular virology capacity 224	
introduced for HIV management, which acted as a launch pad to develop a 225	
comprehensive molecular diagnostic capacity in TB.  226	
 227	
Training and mentorship: Even the simplest technologies can be unsuccessful if the 228	
operators are not well instructed on how to execute them. We conducted two forms of 229	
training, group and site-specific training to offer technical skills, international 230	
networking and site-specific customization of the assay. Confidence building of the 231	
site teams was crucial to perpetuate self-reliance. With this training, researchers 232	
would innovatively ask and answer research questions in TB and other diseases 233	
affecting their region and the country at large.  234	
 235	
Networking: Importantly, we focused on ensuring collaborative networks developed 236	
between the Southern partners, which simplified capacity development. It was easy 237	
for successful models from one site to be adopted easily by another site in the region 238	
in comparison to advice parachuted in from overseas. For example TB laboratory 239	
managers exchanged TB sample processing strategies and learned from each other. 240	
Maputo, Mbeya and Blantyre are geographically close to each other but the TB 241	
laboratories in these cities had neither-shared notes of their work nor learned from 242	
each other. 243	
 244	
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Challenging stereotypes and raising expectation: There is an assumption that cutting 245	
edge molecular solutions are too complex for implementation.  On the contrary, our 246	
experience in the PANBIOME participating countries (Malawi, Mozambique and 247	
Tanzania) shows that molecular techniques can be implemented rapidly and 248	
effectively overcoming supply and servicing challenges. The PANBIOME’s MBLA 249	
was evaluated in four sites with different laboratory capacities, some of which didn’t 250	
have a molecular biology unit for mycobacteriology before. The MBLA involves 251	
inactivation of M. tuberculosis in sputum prior to extraction of RNA and subsequent 252	
quantitative PCR. The inactivation step and the direct isolation of RNA without need 253	
to multiply M. tuberculosis reduces the biosafety requirement of the assay and thus it 254	
can be applied in decentralised laboratories where culture may not be possible. 255	
 256	
Secondly, we found the adaptation rate to the new molecular platform was very high 257	
with only 3 out of 20 scientists and clinicians given short training had molecular 258	
biology background. In addition our pre-study audit found complex molecular 259	
including next generation whole genome sequencing platforms already in use at some 260	
sites. Perhaps we need to raise our expectations of what is possible.   As more 261	
diagnostics move to a molecular platform more ambitious solutions can be applied 262	
and the insensitive and slow culture based diagnosis can be abandoned.   263	
 264	
 265	
WHAT SHOULD HAPPEN NEXT?  266	
 267	
Ensuring development and uptake of diagnostic algorithms: Laboratory testing 268	
does not occur in a clinical vacuum.  It is essential that we develop current diagnostic 269	
methods into practical clinical algorithms that deliver health gains.  For example, a 270	
four-hour viable count assay is of limited value if clinics, and reporting structures do 271	
not allow results to influence clinical decision-making and if the clinicians are not 272	
trained to interpret this new data. We concur with Quaglio and colleagues that 273	
strategic investment in operational research is crucial to bridge the implementation 274	
gap and translate innovations and policy and practice(30). In this respect, dedicated 275	
finance is required to ensure uptake into policy and practice of effective innovations 276	
for TB diagnosis and treatment. Also we need to encourage technology developers to 277	
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create innovative methodologies that are fit for purpose in a resource poor setting.  278	
Diversifying funding sources: Encourage increase in domestic funding to 279	
supplement donor funding. This will diversify the funding available for health 280	
interventions as well as enable researchers to answer questions of national interest. 281	
Meanwhile as domestic funding grows, it is important that the donor community 282	
reinvigorates their commitment to the Algiers declaration for narrowing the 283	
knowledge gap to improve Africa’s health(31). 284	
 285	
Strengthen health systems and supply chains: Since most health care and research 286	
centres in TB high burden countries receive limited direct funding from national 287	
budget, all other funding should be tagged with a fraction of money to support 288	
complementary programmes in the system such as human resource development, 289	
information systems, disease surveillance, instrumentation and other physical 290	
infrastructure upgrades.  291	
 292	
Streamline the procurement system: Negotiating a longstanding understanding with 293	
the government revenue authorities on procurement of clinical laboratory and 294	
research supplies is crucial. This will remove bureaucratic import clearance delays 295	
and ensure timely delivery of essential medicines, reagents and equipment.  296	
 297	
Holistic model for optimising molecular diagnostic capacity 298	
Optimizing molecular diagnostic capacity in for effective management of TB requires 299	
holistic approach (Figure 1). 300	
 301	
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 302	
 303	
Figure 1: The model for optimizing molecular diagnostic capacity to fight TB. Aligning 304	
National – International partnerships, Research and development and Community 305	
empowerment will lead to better financing of health systems and research; production 306	
of effective diagnostics and strong communities who can seek medical attention, afford 307	
and adhere to prescribed medical intervention. 308	
 309	
Strong research and development (R&D) base: We believe that investing in strong 310	
R&D base in the South will solve two specific challenges: generate innovative 311	
diagnostics that are suitable to environmental setting in the South and solve the 312	
procurement bottleneck, for instance it is easy to procure laboratory supplies within or 313	
neighbouring southern country than from Europe or USA. The Southeast African 314	
countries where we operated, give first priority to local suppliers before considering 315	
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overseas suppliers. Partnerships between north-south Industry, NGOs and Academic - 316	
research institutions will help achieve strong R&D base.   317	
 318	
Financing: This is crucial for strengthening R&D, laboratory and clinical 319	
infrastructure and health systems. Funding is also needed to provide essential utilities 320	
such as water and electricity required for laboratories and clinics to operate. A good 321	
funding regime will also accelerate implementation and uptake of innovations into 322	
policy and practice(32).  We believe funding could be achieved through national and 323	
international partnerships including domestic governments and development partners 324	
(donors). Domestic funding has been increasing in some sub-Saharan countries but 325	
there is need for more in order to bridge global funding gap(33).  326	
 327	
Education and Community empowerment: TB is a disease of poverty and despite 328	
availability of good diagnostics and treatment, accessibility remains low in most 329	
communities in sub-Saharan Africa(34). Community education yields improved 330	
health seeking behaviour, increased adherence to treatment and treatment success. 331	
Strategic programmes should be put in place to increase the welfare of affected 332	
communities, affordability of medical interventions as well as mitigating conditions 333	
that promote TB transmission. Better welfare will also increase accessibility to 334	
education and subsequently solve the human resource shortage. 335	
 336	
Effective diagnosis and treatment of TB will be a result of strengthening the three 337	
pillars: research & development, financing and community empowerment. 338	
 339	
Conclusion 340	
 341	
Investing in the uptake and operationalization of the new diagnostic tools in the TB 342	
high burden settings is key to realizing the TB elimination vision(35). The benefits of 343	
this investment go beyond TB. The technical and systemic challenges can be 344	
confronted and solved by taking advantage of current advances in technology and 345	
investing in a truly mutual partnership that benefits both southern and northern 346	
partners equally. Holistic approach embracing research and development, 347	
strengthening of health systems and empowerment of communities is crucial for 348	
achieving sustainable molecular diagnostic capacity. 349	
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